Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2276 participants.
Also called NCT04619927
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 2,276 participants
- Sponsor
- Registry
-
NCT04619927
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Unknown status
Technical summary
Registry record NCT04619927. Randomized; no masking; primary purpose prevention. Start 2021-03-01 (actual); primary completion 2024-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.
- Acronym
- GENPAD
- Condition
- Peripheral Arterial Disease
- Intervention (Genetic)
- Direct CYP2C19 genotyping
- Intervention (Genetic)
- CYP2C19 genotyping at the end of the study
- Intervention (Drug)
- Poor metabolisers
- Intervention (Drug)
- Intermediate metabolisers
- Intervention (Drug)
- Normal metabolisers and unknown metaboliser state
- Lead sponsor
- Radboud University Medical Center
- Collaborator
- ZonMw: The Netherlands Organisation for Health Research and Development
- Collaborator
- Academisch Ziekenhuis Groningen
- Collaborator
- Rijnstate Hospital
- Collaborator
- Bernhoven Hospital
- Collaborator
- Canisius-Wilhelmina Hospital
Record details
- Record id
cardio:ct-nct04619927- Content hash
6951deb151b029208686b50060462f88c83ab8e292be4040a6631290a53fa989